Response to Forman et al.'s "A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativa.".
Zhang N, Xu M
Journal of the American Academy of DermatologyIn the feed 6 Oct 2026, published online 6 Oct 2026, issue 2026 Oct 06, added to PubMed 6 Oct 2026
Topics: Hidradenitis suppurativa
Abstract
PubMed has no abstract for this paper, as is usual for research letters, correspondence and editorials. The publisher’s page has the full paper.
PMID 42838222 · DOI 10.1016/j.jaad.2026.07.147